Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 18/20 | 0.49 |
| ▸ | ITGB6 | P18564 | 12/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.49 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.42 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20140152 | 0.87 | ITGB3 (0.51) | ITGAVITGB3ITGB6ITGA2BITGB5 | |
| SCHEMBL28740582 | 0.87 | ITGB3 (0.51) | ITGAVITGB3ITGB6ITGA2BITGB5 | |
| SCHEMBL20140186 | 0.80 | ITGB3 (0.49) | ITGAVITGB3ITGB6ITGA2B | |
| SCHEMBL20141485 | 0.80 | ALDH1A1 (0.36) | ITGAVITGB3ITGB6ITGA2B | |
| SCHEMBL20141482 | 0.80 | ALDH1A1 (0.36) | ITGAVITGB3ITGB6ITGA2B | |
| SCHEMBL5246958 | 0.77 | CA12 (0.40) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL5246964 | 0.77 | CA12 (0.40) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL6265738 | 0.76 | ITGAV (0.56) | ITGAVITGB3ITGB6ITGA2BITGB5 | |
| SCHEMBL28740589 | 0.76 | ITGB3 (0.48) | ITGAVITGB3ITGB6ITGA2B | |
| SCHEMBL19809630 | 0.75 | ITGAV (0.61) | ITGAVITGB3ITGB6ITGA2BITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11884661-B2 | 3-substituted propionic acids as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-30 | — | — | US | disclosed |
| EP-3538525-B1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3538525-B1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20210188847-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-24 | — | — | US | disclosed |
| US-10968219-B2 | 3-substituted propionic acids as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-06 | — | — | US | disclosed |
| US-20190263808-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-29 | — | — | US | disclosed |
| WO-2018089353-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263808-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB3, ITGB1 | ITGAV 1/4885ITGB3 2/4885ITGB6 15/4885 |
| US-11884661-B2 | 3-substituted propionic acids as αV integrin inhibitors | ITGB3, ITGB1, ITGAV | ITGAV 3/4885ITGB3 1/4885ITGB6 14/4885 |
| US-20210188847-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB3, ITGB1 | ITGAV 1/4885ITGB3 2/4885ITGB6 15/4885 |
| US-10968219-B2 | 3-substituted propionic acids as αV integrin inhibitors | ITGB3, ITGB1, ITGAV | ITGAV 3/4885ITGB3 1/4885ITGB6 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.